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Abstract 
Lentiviral vectors (LVs) are promising delivery systems for gene therapy. To enhance the 
efficiency of target cell transduction by LVs, protocols often include the addition of culture 
additives. In this study, the cationic amphipathic peptide LAH4-L1 
(KKALLAHALHLLALLALHLAHALKKA), a DNA transfection agent, was evaluated for 
its capacity to improve LV infectivity in cell lines and primary cells. Results show that 
LAH4-L1 enhances infectivity of all LV pseudotypes tested, particularly GALVTR-LVs. 
More importantly, LAH4-L1 promotes the transduction of CD34+ hematopoietic stem cells 
with GALVTR-LVs as efficiently as Retronectin, a culture additive used in ex vivo clinical 
protocols involving LVs. The action of LAH4-L1 relies both on the GALVTR-LV adhesion 
and post-adhesion steps. LAH4-L1 represents a new and attractive transduction enhancer for 
hematopoietic gene therapy protocols. 
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Human immunodeficiency virus 1 (HIV-1)-based lentiviral vectors (LVs) are promising 
vehicles for gene therapy. Several clinical trials use LVs for ex vivo transduction of 
hematopoietic stem cells (HSCs) (D'Costa et al., 2009; Naldini, 2011). Transduction of HSCs 
by LVs is initiated by binding of the viral envelope glycoprotein (GP) to cell surface 
receptors. LVs can be efficiently pseudotyped with GPs harboring a broad tropism (e.g. the 
vesicular stomatitis virus GP (VSV-G)), but also GPs harboring a strong hematopoietic 
tropism, such as amphotropic murine leukemia virus GP (MLV-A), modified feline 
endogenous retrovirus RD114 GP (RD114TR) or modified gibbon ape leukemia virus GP 
(GALVTR) (Sandrin et al., 2002). However, a limiting factor that can be encountered during 
viral transduction is the optimal entry of LVs into target cells. One way to circumvent this 
hurdle is the addition of cofactors in transduction protocols like cationic polymers (e.g. 
polybrene) or fibronectin fragments (e.g. Retronectin) (Davis et al., 2004; Pollok and 
Williams, 1999). Since the cationic property appears crucial for many enhancers of retroviral 
infectivity, the capacity of a cationic amphipathic peptide to improve LV infectivity has been 
investigated. Notably, peptides are interesting for their biodegradable property, for their 
reduced size, simplicity of characterization and large-scale production. This study is focused 
on a 26 residues long cationic amphipathic peptide called LAH4-L1 
(KKALLAHALHLLALLALHLAHALKKA), described previously as a potent DNA 
transfection agent (Mason et al., 2006b). 
Pseudotyped LVs were generated by transient transfection of 293T cells with four 
plasmids (ratios 22:1:1:8): the transfer vector plasmid (pRRLsin-PPT-hPGK-eGFP-WPRE) 
encoding the green fluorescent protein (eGFP), the plasmid encoding HIV-1 Rev (pBA.Rev), 
the plasmid encoding HIV-1 gagpol (pKLgagpol), and the appropriate envelope glycoprotein 
constructs: pBA-GALVTR to generate GALVTR-LVs; pHCMV-RD114TR to generate 
RD114TR-LVs; pBA-Ampho to generate MLV-A-LVs; and pMDG to generate VSV-G-LVs. 
 4 
Viral supernatants were collected 48h post-transfection, filtered (0.45µ), aliquoted, and stored 
at -80°C. Viral titers were determined by flow cytometry after infection of HCT116 cells with 
serial dilutions of the vector (Merten et al., 2011). HCT116 cells are commonly used because 
of their high permissivity to numerous lentiviral pseudotypes (Barde et al., 2010). To study 
the effect of LAH4-L1 on LV infectivity, HCT116 cells were transduced either with the four 
LV pseudotypes at the same multiplicity of infection (MOI) of 0.6, or with vector particles 
produced in absence of any envelope glycoprotein (virus-like particles, VLPs, 200ng of 
p24/ml) (Fig. 1A). Briefly, viral supernatants were pre-incubated 15 min at 37°C with 
different concentrations of LAH4-L1, and then loaded onto HCT116 cell layers. After 4 h 
post-transduction, cells were washed and further cultured for 3 days. Transduction efficiency 
was determined by monitoring eGFP expression using flow cytometry. As shown in Fig. 1A, 
LAH4-L1 promotes LV infectivity at different extent, with the highest effect observed for 
GALVTR-LVs (12-fold) and the lowest effect observed for VSV-G-LVs (nearly 3-fold) (Fig. 
1B). Interestingly, VLPs are unable to transduce target cells, even in the presence of LAH4-
L1, indicating that LAH4-L1 is promoting infectivity through an envelope-dependent 
mechanism. 
The GALVTR-LVs are commonly used in gene therapy protocols designed to target 
human hematopoietic progenitors (Jacome et al., 2009). The hCD34+ cells were obtained 
from umbilical cord blood (UCB) samples after column affinity purification and were 
preactivated with a cocktail of cytokines (see Charrier et al., 2007). UCBs for this study were 
obtained in accordance with international ethical principles and French national law under 
declaration N° DC-201-1655 to the French Ministry of Research and Higher Studies. As 
shown in fig. 2A, the half maximal efficient concentration (EC50) of LAH4-L1 on hCD34+ 
cells (3.5 x 10
4 
cells/well) transduced with GALVTR-LVs is around 8µg/ml (the average 
value of maximal transduction was 27% of GFP+ cells). In addition, the half maximal toxic 
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concentration (TC50) of LAH4-L1 on hCD34+ cells was determined. Briefly, hCD34+ cells 
were incubated overnight with the indicated amount of LAH4-L1. Next, the survival rate of 
hCD34+ cells was estimated using the Trypan blue exclusion method under light microscope. 
As shown in Fig. 2B, the TC50 of LAH4-L1 is around 48µg/ml (the average value of survival 
rate in absence of LAH4-L1 was 98.9%). Hence, the LAH4-L1 TC50/EC50 ratio represents a 
6-fold safety index which permits a safe and practical use of this reagent for lentiviral 
transduction of hCD34+ cells. In conclusion, the optimal concentration of LAH4-L1, with no 
apparent toxicity on hCD34+ cells, has been defined around 12µg/ml (transduction rate of 
88±14% and survival rate of 100±02%).  
Next, LAH4-L1 was able to promote the lentiviral transduction of hCD34+ cells from 
several UCB donors (Fig. 2C). It is important to note that the transduction with GALVTR-
LVs is nearly undetectable in absence of any transduction enhancer, while the effect of 
LAH4-L1 reproducibly increased transduction levels of hCD34+ cells in a vector-dose 
dependent manner (Fig. 2C). 
Since hCD34+ cells are typically transduced with GALVTR-LVs pre-adsorbed onto 
Retronectin (Takara bio)-coated wells (Jacome et al., 2009; Pollok and Williams, 1999), the 
ability of LAH4-L1 to promote hCD34+ cells transduction was tested in comparison with 
Retronectin. The dynamic preloading protocol of GALVTR-LVs onto retronectin coated 
plates (20µg/cm
2
) has been described previously (Jacome et al., 2009). In absence of 
Retronectin, hCD34+ cells were transduced with GALVTR-LVs pre-incubated 15 min with 
LAH4-L1. After 6 h of transduction at 37°C, fresh medium was added to each well and 
transduction efficiency was evaluated by flow cytometry 4 days later. As shown in Fig. 2D, 
LAH4-L1 is promoting hCD34+ cells transduction as efficiently as Retronectin and with no 
detectable toxicity (data not shown). 
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To determine whether LAH4-L1 is acting on the adhesion step and/or the post-binding 
events, we adapted a virus binding assay, described previously (Gummuluru et al., 2003) and 
depicted in Fig. 3A. Briefly, HCT116 cells were incubated with GALVTR-LVs during 3 h at 
4°C to allow for viral adhesion, in the absence or presence of LAH4-L1 or polybrene (Sigma-
Aldrich). Unbound GALVTR-LVs were then washed away and cells were either lysed to 
determine the amount of membrane bound p24 (ELISA p24 kit, Perkin Elmer) normalized to 
total protein contents (BCA protein assay, Pierce) or cultured for an additional 2 days to 
estimate transduction efficiency using flow cytometry (GFP+ cell percentages). As shown in 
Fig. 3B, LAH4-L1 is as efficient as polybrene to potentiate the adhesion step, probably 
through the cationic charges of these two compounds, leading to the neutralization of negative 
charges present on the target cell surface. Interestingly, the difference between polybrene and 
LAH4-L1 is highlighted on the post-binding events (Fig. 3C and D). After an extensive wash 
of unbound GALVTR-LVs, we observed that viral particles bound to cell surface are more 
prone for entry and subsequent transduction steps in presence of LAH4-L1 (index 2.6) than in 
presence of polybrene (index 1.7). 
Amphipathic peptides such as LAH4-L1 interact with membrane lipids, adopt a 
transmembrane orientation at neutral pH and in consequence weakly disrupt the plasma 
membrane (Mason et al., 2006a). Since the lipid mixing between viral and plasma membrane 
seems a prerequisite to viral envelope engagement for viral pore formation (Chien et al., 
2009), it is tempting to speculate that LAH4-L1, with its high affinity to membrane lipids,  
may act at the level of the entry step, first, by neutralizing anionic lipids and heparan sulfates 
and also by locally destabilizing the membrane lipid leaflet, leading finally to an optimization 
of the lipid mixing step independently of the envelope used to pseudotype the lentiviral 
vector. Furthermore, the fact that the optimal concentration of LAH4-L1 to promote lentiviral 
transduction (12µg/ml) is too low to promote an efficient DNA transfection (not shown) 
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suggests that LAH4-L1 exerts these two functions through different molecular mechanisms. 
In conclusion, LAH4-L1 represents a new and attractive transduction cofactor for future gene 
therapy developments involving LVs. 
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Figure legends 
 
Fig. 1.  Capacity of LAH4-L1 to enhance lentiviral transduction. (A) A variety of GFP-
encoding LV (GALVTR-LVs, MLV-A-LVs, RD114TR-LVs, VSV-G-LVs and VLPs) were 
used to transduce HCT116 cells (1.2 x 10
5
 TU/ml, MOI 0.6 or 200 ng/ml of HIV-1 p24 for 
VLPs) in absence or presence of 3, 6 or 12 µg/ml of LAH4-L1. Data are shown as the average 
percentage of GFP+ HCT116 cells ± standard deviations (SD) (n=3). (B) Data obtained in (A) 
are represented as the fold of enhancement mediated by LAH4-L1 with the mock condition 
normalized to one. 
 
Fig. 2.  Efficient transduction of hCD34+ cells with GALVTR-LVs in presence of LAH4-L1. 
(A) Determination of the EC50 of LAH4-L1 on hCD34+ cells transduced with GALVTR-LVs 
(10
6
 TU/ml). Transduction efficiencies (percentage of GFP+ cells) were obtained 4 to 5 days 
post-transduction (n=4). Data are normalized to the maximum effect observed ± SD. (B) 
Determination of the TC50 of LAH4-L1. hCD34+ cells were incubated overnight with the 
indicated amount of LAH4-L1 (n=5). Next, the survival rate was estimated and normalized to 
the control condition ± SD. (C) Transduction of hCD34+ cells with two different 
concentrations of GALVTR-LVs (1 and 2 x 10
6
 TU/ml) in the absence or presence of LAH4-
L1 (12µg/ml). Data are obtained from 7 different cord blood donors in simplicate or duplicate. 
(D) hCD34+ cells from two different donors were transduced in duplicate with GALVTR-
LVs either pre-incubated with LAH4-L1 (12 µg/ml) or pre-loaded onto retronectin coated 
plates (20 µg/cm
2
). Data are represented as the average percentage of GFP+ cells ± SD 
(**p<0.01, *p<0.05, Mann-Whitney test). 
 
Fig. 3.  GALVTR-LV binding assay in presence of LAH4-L1. (A) Protocol used for the virus 
binding assay is depicted. The experiment was done in triplicate. (B) Membrane bound p24 
was determined using an ELISA p24 kit as described in the text and normalized to total 
protein content (total membrane of bound p24 in pg ± SD). (C) Transduction efficiencies were 
determined as in Fig.1A and were represented as the average percentage of GFP+ cells ± SD. 
(D) Transduction efficiencies were normalized to the number of membrane bound p24. An 
arbitrary unit of one was assigned to the “none” condition. (*p<0.05, not statistically 
significant (ns), Mann-Whitney test). 
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